Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%

  • Novo Nordisk said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company's sales and promotion of cheaper knock-offs of the weight loss drug Wegovy.  Novo Nordisk in April said it would offer Wegovy through several telehealth companies, such as Hims & Hers, to expand access to the blockbuster injection now that it is no longer in short supply in the U.S.